We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alzheimer's Disease Mouse Model Links Beta-Amyloid Deposits to Tau Protein Hyperphosphorylation

By LabMedica International staff writers
Posted on 14 Jul 2016
Neurodegenerative disease researchers have created a genetically engineered mouse model of Alzheimer's disease that is expected to facilitate the study of the molecular mechanisms that underlie the disorder.

A central question in Alzheimer’s disease (AD) is whether the neuritic plaque is necessary and sufficient for the development of tau pathology. More...
Hyperphosphorylation of all six tau protein isoforms can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease and other tauopathies. When misfolded, this otherwise very soluble protein can form extremely insoluble aggregates that contribute to a number of neurodegenerative diseases.

Hyperphosphorylation of the tau protein has been demonstrated within neurites surrounding beta-amyloid deposits in AD mouse models, but the pathological conversion of tau was absent. Likewise, expression of a human tau repeat domain in mice was not sufficient to drive the pathological conversion of tau.

To develop a better understanding of how tau hyperphosphorylation was linked to beta-amyloid neuritis, investigators at Johns Hopkins University (Baltimore, MD, USA) genetically engineered an A-beta-amyloidosis mouse model that expressed the human tau repeat domain.

The investigators found that in these mice, the neuritic plaque facilitated the pathological conversion of wild-type tau. They showed that this tau fragment seeded the neuritic plaque-dependent pathological conversion of wild-type tau that spread from the cortex and hippocampus to the brain stem. These results established that in addition to the neuritic plaque, a second determinant was required to drive the conversion of wild-type tau.

"In Alzheimer's disease, tau bunches up inside the nerve cells and beta-amyloid clumps up outside these cells, mucking up the nerve cells controlling memory," said senior author Dr. Philip C. Wong, professor of pathology at Johns Hopkins University. "For the first time, we think we understand that the accumulation of amyloid plaque alone can damage the brain, but that is actually not sufficient to drive the loss of nerve cells or behavioral and cognitive changes. What appears to be needed is a second insult - the conversion of tau - as well."

Related Links:
Johns Hopkins University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.